Biogen Inc.: FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA (tocilizumab)
CAMBRIDGE, Mass., Dec. 09, 2022Inc. (Nasdaq: BIIB) - announced that the U.S. Food and Drug Administration (FDA) has accepted for review the abbreviated Biologics License Application (aBLA) for BIIB800